The Original Human-on-a-Chip Company

Pioneers for Reducing Animal Testing through Emulating Biology

Row edge-slant Shape Decorative svg added to bottom

the leading light for human-on-a-chip Research

Hesperos is named for Venus in the evening sky. Like her, we are a leading light, providing world-class research in disease modeling and drug testing through our use of human-on-a-chip systems. Our patent positions and the over 20 years of expertise of both Drs. Shuler and Hickman make us the company to work with for your most difficult problems as well as for cost competitive, routine, human-on-a-chip assays.

The hesperos difference

Hesperos, Inc. brings together biologists, surface chemists, and engineers in order to produce some of the worlds most advanced organs-on-chips. From gene expression to electrophysiology, our biologists recreate key components of various organs. Chemically patterned microchips are engineered to enable real-time monitoring of organ activity. Finally, our engineers utilize sophisticated measurement techniques in order to detect and quantify minute changes.  The result of this collaboration is an ability to study therapeutics in a way which was previously only possible in clinical trials.

Row edge-slant Shape Decorative svg added to top

As Featured In

Industries We Serve

Rare Disease

Pharmacology

Chemicals, Nutraceuticals, and Supplements

Row edge-slant Shape Decorative svg added to top
Row edge-slant Shape Decorative svg added to bottom

Latest News

Advanced Science Cover Page Features Hesperos’ Malaria-on-a-Chip Model

By Hesperos | 6 January 2026

Featured on the cover of Advanced Science, our study presents a human-derived Malaria-on-a-Chip system that captures the biology of infection and delivers actionable insights for real-world therapeutic translation.

Announcing Strategic Channel Sales Partnership with AsedaSciences for Better Predictive, More Efficient, & Lower Cost Drug/Product Development

By Hesperos | 17 December 2025

Hesperos and AsedaSciences announce a strategic channel sales partnership combining Human-on-a-Chip® and AI-driven 3RnD® to advance safer, more efficient drug and chemical development.

Human-on-a-Chip® Advancements: Industry Recognition and New Research Published

By Hesperos | 9 December 2025

Hesperos’ Human-on-a-Chip® technology earns recognition in a Nature Lab Animal article highlighting advancements in human-relevant, new alternative methods (NAMs) models and publishes new research advancing its sarcopenia-on-a-chip system.

Hesperos and Oriental Yeast Co., Ltd. Announce Strategic Partnership to Expand Human-on-a-Chip® Services Across Asia

By Hesperos | 23 October 2025

Hesperos and Oriental Yeast Co. form a strategic partnership to expand access to Human-on-a-Chip® services across Asia, accelerating safer, more effective preclinical drug development.

Hesperos Awarded NIH Phase IIB Grant to Help Prevent Drug-Induced Dementia

By Hesperos | 17 October 2025

Hesperos and GalenusRx receive $3M NIH grant to study drug-induced dementia using Human-on-a-Chip® systems and improve medication safety for older adults.

Press Release: Hesperos and Bayer Consumer Health Develop First Human-on-a-Chip® Model of Stress-Induced Cognitive Dysfunction

By Hesperos | 7 October 2025

Hesperos and Bayer unveil the first Human-on-a-Chip® model replicating stress-induced cognitive decline to advance non-animal CNS drug research.

Hesperos Demonstrates First Digital Twin of Human Disease Using Organ-on-a-Chip Platform

By Hesperos | 22 July 2025

PRESS RELEASE Key Results from Study First Digital Twin from Organ-on-a-Chip: Hesperos successfully created what’s believed to be the first digital twin derived from an organ-on-a-chip (microphysiological) system.Multi-Organ Human System: The study utilized a multi-organ system … Read More

Press Release: Announcing collaboration with Psilera to advance development of PSIL-006 for Frontotemporal Dementia

By Hesperos | 9 June 2025

Key Takeaways Hesperos aims to accelerate the preclinical development of Psilera’s lead compound, PSIL-006, targeting frontotemporal dementia (FTD).   Press Release “Our platform offers a unique opportunity to assess the compound’s effects on neural tissues derived from … Read More

PharmaVoice Interviews Hesperos President and CEO on the future of New Approach Methodologies (NAMs)

By Hesperos | 9 May 2025

Highlights   PharmaVoice interviewed Michael Shuler, President and Cofounder of Hesperos, and Lawrence Florin, CEO of Hesperos, along with other pharma leaders, about the future of New Approach Methodologies (NAMs) They discussed the recent pronouncements from … Read More

NIH announces new initiative to prioritize human-based research technologies

By Hesperos | 6 May 2025

“For decades, our biomedical research system has relied heavily on animal models. With this initiative, NIH is ushering in a new era of innovation… This human-based approach will accelerate innovation, improve healthcare outcomes, and deliver life-changing … Read More

About Our Team

Hesperos, Inc, is a leader in efforts to characterize an individual’s biology with human-on-a-chip microfluidic systems. Founders Michael L. Shuler and James J. Hickman have been at the forefront of every major scientific discovery in this realm, from individual organ-on-a-chip constructs to fully functional, interconnected multi-organ systems which they coined "human-on-a-chip."

Row edge-slant Shape Decorative svg added to top

Simulating Organ Function

Unlike other tests that extrapolate organ function based on biomarker activity and protein analysis, our models are working systems that recreate muscle and tissue function as well as neural and inter-organ communication. The resulting functional reports closely correlate to what clinicians observe in human clinical trials.

Data Driven Analysis

Our systems generate thousands of data points which correlate to key functional aspects of each organ.  Our custom analyses are then able to parse the data quickly and fruitfully to identify subtle changes in function alongside large-scale shifts in morphology and behavior, yielding insights into each drug.

Interested in working with hesperos?